Cargando…
Selective delivery of low-affinity IL-2 to PD-1(+) T cells rejuvenates antitumor immunity with reduced toxicity
PD-1 signaling on T cells is the major pathway that limits T cell immunity, but the efficacy of anti–PD-1 therapy has been limited to a small proportion of patients with advanced cancers. We fortuitously observed that anti–PD-1 therapy depends on IL-2 signaling, which raises the possibility that a l...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
American Society for Clinical Investigation
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8803347/ https://www.ncbi.nlm.nih.gov/pubmed/35104810 http://dx.doi.org/10.1172/JCI153604 |